See more : Aecc Aero-Engine Control Co.,Ltd. (000738.SZ) Income Statement Analysis – Financial Results
Complete financial analysis of ImmuCell Corporation (ICCC) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of ImmuCell Corporation, a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Organovo Holdings, Inc. (ONVO) Income Statement Analysis – Financial Results
- Golden Sky Minerals Corp. (LCKYF) Income Statement Analysis – Financial Results
- Gold Lion Resources Inc. (GL.CN) Income Statement Analysis – Financial Results
- Mensch und Maschine Software SE (MUM.DE) Income Statement Analysis – Financial Results
- Ace Edulink Co., Ltd. (6764.TWO) Income Statement Analysis – Financial Results
ImmuCell Corporation (ICCC)
About ImmuCell Corporation
ImmuCell Corporation, an animal health company, develops, manufactures, and markets products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. It offers First Defense, an orally delivered scours preventive product for newborn dairy and beef calves; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. The company also provides California Mastitis Test that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, including a whey protein concentrate for the nutritional and feed supplement markets. In addition, it is involved in developing Re-Tain, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 | 1991 | 1990 | 1989 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 17.47M | 18.57M | 19.24M | 15.34M | 13.72M | 10.99M | 10.43M | 9.54M | 10.23M | 7.60M | 6.01M | 5.39M | 5.11M | 4.39M | 4.51M | 4.63M | 6.07M | 4.80M | 4.98M | 3.70M | 3.36M | 6.18M | 6.68M | 5.64M | 4.91M | 4.50M | 4.60M | 4.40M | 4.90M | 4.40M | 3.90M | 3.10M | 2.20M | 3.00M | 2.80M |
| Cost of Revenue | 13.08M | 10.92M | 10.59M | 8.48M | 6.98M | 5.79M | 5.21M | 4.12M | 3.98M | 3.15M | 2.95M | 2.34M | 2.30M | 2.08M | 2.11M | 2.56M | 2.27M | 1.88M | 1.63M | 1.45M | 1.35M | 2.80M | 3.22M | 2.67M | 2.05M | 1.90M | 1.70M | 1.80M | 1.80M | 1.80M | 1.70M | 1.40M | 1.30M | 1.10M | 1.50M |
| Gross Profit | 4.40M | 7.65M | 8.66M | 6.86M | 6.74M | 5.19M | 5.22M | 5.42M | 6.25M | 4.45M | 3.06M | 3.05M | 2.81M | 2.30M | 2.40M | 2.07M | 3.80M | 2.92M | 3.35M | 2.25M | 2.01M | 3.39M | 3.46M | 2.97M | 2.86M | 2.60M | 2.90M | 2.60M | 3.10M | 2.60M | 2.20M | 1.70M | 900.00K | 1.90M | 1.30M |
| Gross Profit Ratio | 25.16% | 41.19% | 44.98% | 44.73% | 49.11% | 47.28% | 50.05% | 56.80% | 61.11% | 58.56% | 50.95% | 56.67% | 55.05% | 52.49% | 53.25% | 44.77% | 62.62% | 60.79% | 67.21% | 60.80% | 59.87% | 54.74% | 51.85% | 52.66% | 58.21% | 57.78% | 63.04% | 59.09% | 63.27% | 59.09% | 56.41% | 54.84% | 40.91% | 63.33% | 46.43% |
| Research & Development | 4.39M | 4.49M | 4.17M | 4.35M | 3.69M | 3.52M | 2.05M | 1.24M | 1.24M | 2.18M | 1.15M | 917.60K | 1.72M | 1.49M | 1.64M | 1.75M | 1.58M | 965.93K | 1.27M | 1.09M | 1.35M | 1.05M | 849.00K | 922.35K | 812.89K | 1.00M | 1.10M | 1.30M | 1.50M | 1.40M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 2.13M | 2.26M | 1.73M | 1.72M | 1.69M | 1.74M | 1.52M | 1.45M | 1.29M | 1.16M | 939.19K | 918.44K | 856.61K | 849.06K | 872.53K | 926.29K | 1.35M | 1.18M | 1.14M | 1.03M | 1.09M | 1.80M | 1.94M | 1.50M | 1.33M | 1.50M | 1.40M | 1.30M | 1.40M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 3.09M | 5.45M | 4.23M | 3.89M | 4.01M | 3.82M | 3.42M | 1.83M | 1.61M | 1.32M | 986.77K | 973.22K | 869.87K | 650.89K | 410.74K | 569.71K | 0.00 | 401.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 5.22M | 5.45M | 4.23M | 3.89M | 4.01M | 3.82M | 3.42M | 3.29M | 2.89M | 2.48M | 1.93M | 1.89M | 1.73M | 1.50M | 1.28M | 1.50M | 1.35M | 1.18M | 1.14M | 1.03M | 1.09M | 1.80M | 1.94M | 1.50M | 1.33M | 1.50M | 1.40M | 1.30M | 1.40M | 1.30M | 2.20M | 1.90M | 2.20M | 2.30M | 2.10M |
| Other Expenses | 0.00 | -187.00K | -326.00K | 348.00K | -314.00K | -413.00K | -195.00K | -24.85K | 5.64K | -3.90K | 31.90K | 8.10K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 133.16K | 101.54K | 100.00K | 100.00K | 100.00K | 200.00K | 200.00K | 100.00K | 100.00K | 100.00K | 100.00K | 100.00K |
| Operating Expenses | 9.62M | 9.95M | 8.40M | 8.24M | 7.69M | 7.34M | 5.46M | 4.53M | 4.13M | 4.66M | 3.08M | 2.81M | 3.45M | 2.99M | 2.93M | 3.24M | 2.93M | 2.15M | 2.41M | 2.13M | 2.44M | 2.85M | 2.79M | 2.55M | 2.24M | 2.60M | 2.60M | 2.70M | 3.10M | 2.90M | 2.30M | 2.00M | 2.30M | 2.40M | 2.20M |
| Cost & Expenses | 23.22M | 20.87M | 18.99M | 16.72M | 14.68M | 13.13M | 10.67M | 8.65M | 8.11M | 7.80M | 6.03M | 5.14M | 5.74M | 5.08M | 5.04M | 5.80M | 5.20M | 4.03M | 4.05M | 3.58M | 3.79M | 5.65M | 6.01M | 5.22M | 4.29M | 4.50M | 4.30M | 4.50M | 4.90M | 4.70M | 4.00M | 3.40M | 3.60M | 3.50M | 3.70M |
| Interest Income | 0.00 | 153.10K | 18.81K | 27.44K | 118.28K | 14.30K | 16.91K | 54.66K | 19.17K | 15.55K | 12.49K | 17.20K | 15.00K | 26.00K | 96.29K | 204.48K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 340.88K | 314.36K | 412.69K | 431.79K | 427.78K | 218.57K | 161.70K | 80.24K | 57.83K | 66.69K | 75.27K | 81.00K | 22.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 2.72M | 2.49M | 2.47M | 2.36M | 2.27M | 1.52M | 904.44K | 802.38K | 529.26K | 448.92K | 417.20K | 402.52K | 418.37K | 419.51K | 424.44K | 399.10K | 788.90K | 278.52K | 643.62K | 278.52K | 256.27K | 236.77K | 177.00K | 133.16K | 101.54K | 100.00K | 100.00K | 100.00K | 200.00K | 200.00K | 100.00K | 100.00K | 100.00K | 100.00K | 100.00K |
| EBITDA | -2.50M | 349.99K | 2.72M | 1.65M | 1.43M | 88.44K | 684.53K | 1.72M | 2.65M | 251.30K | 692.04K | 672.82K | -192.31K | -241.90K | -4.07K | -768.49K | 1.66M | 1.05M | 1.58M | 399.29K | -172.76K | 769.91K | 847.61K | 546.53K | 716.51K | 100.00K | 400.00K | 0.00 | 200.00K | -100.00K | 0.00 | -200.00K | -1.30M | -400.00K | -800.00K |
| EBITDA Ratio | -14.33% | -12.38% | 1.34% | -8.99% | -6.95% | -25.91% | -2.33% | 18.05% | 26.13% | 3.31% | 7.31% | 12.43% | -3.90% | -5.58% | -2.32% | -16.64% | 27.45% | 21.95% | 31.63% | 10.80% | -37.89% | -2.68% | 8.48% | 9.70% | 16.57% | 2.22% | 8.70% | 2.27% | 4.08% | -4.55% | 0.00% | -6.45% | -59.09% | -13.33% | -28.57% |
| Operating Income | -5.75M | -2.30M | -2.20M | -1.38M | -954.00K | -1.45M | -243.00K | 890.20K | 2.12M | -206.40K | -19.55K | 245.00K | -632.73K | -690.28K | -527.03K | -1.17M | 872.10K | 770.68K | 938.03K | 120.77K | -429.03K | 533.14K | 671.00K | 413.37K | 614.97K | 0.00 | 300.00K | -100.00K | 0.00 | -300.00K | -100.00K | -300.00K | -1.40M | -500.00K | -900.00K |
| Operating Income Ratio | -32.90% | -12.38% | -11.45% | -8.99% | -6.95% | -13.17% | -2.33% | 9.33% | 20.75% | -2.72% | -0.33% | 4.55% | -12.38% | -15.74% | -11.69% | -25.20% | 14.37% | 16.05% | 18.82% | 3.27% | -12.78% | 8.62% | 10.05% | 7.33% | 12.53% | 0.00% | 6.52% | -2.27% | 0.00% | -6.82% | -2.56% | -9.68% | -63.64% | -16.67% | -32.14% |
| Total Other Income/Expenses | -21.89K | -187.19K | -326.51K | 348.10K | -313.51K | -413.48K | -195.64K | -131.88K | -58.77K | -49.05K | 224.81K | -52.85K | -63.96K | 6.87K | 98.53K | 206.94K | 271.54K | 263.37K | 133.05K | 56.42K | 1.15M | 948.24K | 26.04K | 62.51K | -97.13K | 0.00 | 0.00 | 100.00K | 100.00K | 100.00K | 100.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Before Tax | -5.77M | -2.49M | -69.00K | -1.03M | -1.27M | -1.86M | -438.00K | 758.32K | 2.06M | -255.45K | 205.26K | 192.15K | -696.68K | -683.41K | -428.50K | -960.65K | 1.14M | 1.03M | 1.07M | 177.19K | 716.38K | 1.48M | 697.00K | 475.89K | 517.84K | 0.00 | 0.00 | 0.00 | 0.00 | -200.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Before Tax Ratio | -33.02% | -13.39% | -0.36% | -6.73% | -9.24% | -16.93% | -4.20% | 7.95% | 20.17% | -3.36% | 3.42% | 3.57% | -13.63% | -15.58% | -9.50% | -20.73% | 18.84% | 21.54% | 21.49% | 4.79% | 21.34% | 23.95% | 10.44% | 8.44% | 10.55% | 0.00% | 0.00% | 0.00% | 0.00% | -4.55% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 4.63K | 8.00K | 9.00K | -10.00K | 28.00K | 462.00K | -270.00K | 249.87K | 850.31K | -88.29K | 87.87K | 102.64K | -287.17K | -298.73K | -212.01K | -492.10K | 481.51K | 386.91K | 363.31K | 33.67K | 305.16K | 595.15K | 277.00K | -1.75M | 64.13K | 100.00K | 0.00 | 100.00K | 0.00 | -200.00K | 0.00 | -100.00K | 0.00 | 100.00K | 100.00K |
| Net Income | -5.77M | -2.49M | -78.00K | -1.02M | -1.30M | -2.32M | -168.00K | 508.45K | 1.21M | -167.16K | 117.40K | 89.51K | -409.51K | -384.68K | -216.49K | -468.56K | 662.14K | 647.14K | 707.78K | 143.52K | 411.22K | 886.24K | 420.00K | 2.22M | 550.84K | -100.00K | 300.00K | -100.00K | 0.00 | -100.00K | 0.00 | -200.00K | -1.40M | -600.00K | -1.00M |
| Net Income Ratio | -33.05% | -13.43% | -0.41% | -6.66% | -9.44% | -21.14% | -1.61% | 5.33% | 11.86% | -2.20% | 1.95% | 1.66% | -8.01% | -8.77% | -4.80% | -10.11% | 10.91% | 13.48% | 14.20% | 3.88% | 12.25% | 14.33% | 6.29% | 39.43% | 11.22% | -2.22% | 6.52% | -2.27% | 0.00% | -2.27% | 0.00% | -6.45% | -63.64% | -20.00% | -35.71% |
| EPS | -0.75 | -0.32 | -0.01 | -0.14 | -0.19 | -0.42 | -0.03 | 0.12 | 0.40 | -0.06 | 0.04 | 0.03 | -0.14 | -0.13 | -0.07 | -0.16 | 0.23 | 0.22 | 0.25 | 0.05 | 0.15 | 0.32 | 0.15 | 0.84 | 0.23 | -0.04 | 0.11 | -0.04 | 0.01 | -0.06 | -0.01 | -0.11 | -0.69 | -0.28 | -0.50 |
| EPS Diluted | -0.75 | -0.32 | -0.01 | -0.14 | -0.19 | -0.42 | -0.03 | 0.12 | 0.38 | -0.06 | 0.04 | 0.03 | -0.14 | -0.13 | -0.07 | -0.16 | 0.22 | 0.21 | 0.24 | 0.05 | 0.15 | 0.32 | 0.15 | 0.79 | 0.22 | -0.04 | 0.10 | -0.04 | 0.01 | -0.06 | -0.01 | -0.11 | -0.69 | -0.28 | -0.50 |
| Weighted Avg Shares Out | 7.70M | 7.75M | 7.59M | 7.21M | 6.82M | 5.49M | 4.95M | 4.23M | 3.04M | 3.03M | 3.02M | 3.02M | 2.98M | 2.97M | 2.96M | 2.89M | 2.90M | 2.89M | 2.82M | 2.76M | 2.74M | 2.77M | 2.80M | 2.63M | 2.43M | 2.43M | 2.73M | 2.73M | 2.29M | 1.67M | 2.64M | 1.82M | 2.03M | 2.14M | 1.99M |
| Weighted Avg Shares Out (Dil) | 7.75M | 7.75M | 7.59M | 7.21M | 6.82M | 5.49M | 4.95M | 4.34M | 3.17M | 3.03M | 3.09M | 3.11M | 2.98M | 2.97M | 2.96M | 2.89M | 3.03M | 3.05M | 3.00M | 2.97M | 2.82M | 2.77M | 2.80M | 2.82M | 2.52M | 2.43M | 3.00M | 2.73M | 2.50M | 1.67M | 2.64M | 1.82M | 2.03M | 2.14M | 1.99M |
ImmuCell Corporation (ICCC) CEO Michael Brigham on Q1 2021 Results - Earnings Call Transcript
ImmuCell Corporation (ICCC) CEO Michael Brigham on Q1 2021 Results - Earnings Call Transcript
ImmuCell to Announce Unaudited Financial Results for the First Quarter Ended March 31, 2021
Conference Call Scheduled for Friday, May 14, 2021 at 9:00 AM ET Conference Call Scheduled for Friday, May 14, 2021 at 9:00 AM ET
ImmuCell Closes $4,250,000 Equity Financing
PORTLAND, Maine, April 14, 2021 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of dairy and beef cattle,...
ImmuCell Announces Preliminary, Unaudited Sales Results for First Quarter of 2021
PORTLAND, Maine, April 07, 2021 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of dairy and beef cattle,...
ImmuCell Corporation (ICCC) CEO Michael Brigham on Q4 2020 Results - Earnings Call Transcript
ImmuCell Corporation (ICCC) CEO Michael Brigham on Q4 2020 Results - Earnings Call Transcript
ImmuCell to Announce Unaudited Financial Results for the Year Ended December 31, 2020
Conference Call Scheduled for Tuesday, February 23, 2021 at 9:00 AM ET Conference Call Scheduled for Tuesday, February 23, 2021 at 9:00 AM ET
ImmuCell Announces Restructuring of its Bank Debt
PORTLAND, Maine, Dec. 15, 2020 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of dairy and beef cattle,...
ImmuCell Corporation (ICCC) CEO Michael Brigham on Q3 2020 Results - Earnings Call Transcript
ImmuCell Corporation (ICCC) CEO Michael Brigham on Q3 2020 Results - Earnings Call Transcript
ImmuCell to Announce Unaudited Financial Results for Third Quarter of 2020
Conference Call Scheduled for Friday, November 13, 2020 at 9:00 AM ET Conference Call Scheduled for Friday, November 13, 2020 at 9:00 AM ET
ImmuCell Corporation 2020 Q2 - Results - Earnings Call Presentation
The following slide deck was published by ImmuCell Corporation in conjunction with their 2020 Q2 earnings call.
Source: https://incomestatements.info
Category: Stock Reports